Back to results
US 10,870,624 B2Granted
Histone deacetylase inhibitors
AssigneeKarus Therapeutics Limited
InventorsStephen J. Shuttleworth, Cyrille D. Tomassi, Alexander R. L. Cecil, Somhairle MacCormick, William J. Nodes, Franck A. Silva
Life of this patent
Estimating the term…
Abstract
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.
Claims5
A compound of the formula
- or a pharmaceutically acceptable salt thereof, wherein:
- R′ attached to L is independently selected for each occurrence from the group consisting of H, C1alkyl, O—(C1alkyl), and halogen;
- R′ attached to R3 is hydrogen or halogen;
- L is independently selected for each occurrence from the group consisting of pyrazinyl, pyridyl, and pyrimidinyl, wherein both L groups are directly bonded to the N by a carbon;
- W is
- each R2 is hydrogen;
- and
- R3 is phenylene.
5 more elements
A compound selected from the group consisting of:
- N-hydroxy-4-((pyrazin-2-yl(pyridin-2-yl)amino)methyl)benzamide;
- 4-(((5-fluoropyridin-2-yl)(pyrazin-2-yl)amino)methyl)-N-hydroxybenzamide;
- N-hydroxy-4-{[(pyrazin-2-yl)(pyrimidin-4-yl)amino]methyl}benzamide;
- 3-fluoro-N-hydroxy-4-{[(pyrazin-2-yl)(pyrimidin-4-yl)amino]methyl}benzamide;
- 4-{[bis(pyrazin-2-yl)amino]methyl}-N-hydroxybenzamide;
- and 4-{[bis(pyrazin-2-yl)amino]methyl}-3-fluoro-N-hydroxybenzamide;
- or a pharmaceutically acceptable salt thereof.
4 more elements
Dependencies are inferred from the claim text.